Year: 2018
Type: article
Abstract: Historically, advanced non-small cell lung cancer (NSCLC) has been a devastating cancer diagnosis with an aggressive course and poor prognosis despite extensive and toxic therapy, however with the advent of personalized therapy targeting molecular aberrancies, the field of lung cancer has made significant advances in outcomes with concomitant improvements in toxicity profiles (1,2).
Source: Journal of Thoracic Disease
Authors: Meghan Kaumaya, Balazs Halmos
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W2900189993